查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542920

全球敗血症診斷市場 - 2024-2031

Global Sepsis Diagnostic Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年，全球敗血症診斷市場規模達到7.1013億美元，預計2031年將達到14.3524億美元，2024-2031年預測期間複合年成長率為9.5%。

敗血症是一種危及生命的疾病，當人體免疫系統對感染反應過度，導致器官功能障礙時，就會發生敗血症。身體的反應會損害其組織和器官，如果不及時發現和治療，可能會導致休克、多重器官衰竭，甚至死亡。

進行血液檢查和其他實驗室檢查（例如尿液、傷口液體、呼吸道黏液和唾液）來診斷病情。

市場動態：

驅動程式和限制

傳染病負擔日益沉重

如果傳染性感染未及時發現和治療，可能會發展為膿毒症等嚴重疾病。因此，人們更加重視可能發展為敗血症的感染的早期診斷。敗血症的診斷測試可幫助醫療保健提供者及早發現病情，從而進行適當的干涉和管理。 HAI 是院內感染，可顯著導致敗血症病例。

隨著醫療保健相關感染的持續上升，越來越需要精確的診斷工具來監測患者並在這些環境中及早診斷膿毒症。

在歐洲，就殘疾和過早死亡而言，六種最常見的醫院感染的負擔據計算是其他 32 種傳染病負擔的兩倍。

此外，根據 2023 Balasubramanian 等人發表的研究，全球每年估計發生 1.36 億例與醫療保健相關的抗生素抗藥性感染病例。因此，傳染病負擔的增加預計將推動市場成長。

診斷工具成本高

自動診斷儀器和生物標記測試可能非常昂貴。高額的前期費用可能會導致醫療機構的整體採用率下降。這直接導致敗血症診斷市場成長放緩。儘管有這些限制，醫院仍將繼續使用較舊的、較便宜的方法。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 傳染病負擔日益加重
    • 限制
      • 診斷工具成本高
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 報銷分析
  • 專利分析
  • SWOT分析
  • DMI 意見

第 6 章：依產品

  • 儀器儀表
  • 軟體
  • 血液培養介質
  • 測定和試劑
  • 其他

第 7 章：按技術

  • 流式細胞儀
  • 微生物學
  • 生物標記
  • 分子診斷
  • 微流控
  • 其他

第 8 章：透過診斷方法

  • 自動診斷
  • 常規診斷

第9章：按病原體

  • 黴菌性敗血症
  • 細菌性敗血症
    • 革蘭氏陽性細菌敗血症
    • 革蘭氏陰性細菌敗血症
  • 其他病原體

第 10 章：最終用戶

  • 醫院
  • 病理學和參考實驗室
  • 其他

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • Thermo Fisher Scientific Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Bruker Corporation
  • Merck Millipore
  • Siemens Healthineers
  • Becton, Dickinson, and Company
  • Hoffmann-LA Roche Ltd
  • T2 Biosystems, Inc.
  • Response Biomedical Corp.
  • BioMerieux SA
  • Immunexpress Inc. (LIST NOT EXHAUSTIVE)

第 14 章：附錄

簡介目錄
Product Code: CD1257

Report Overview

The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.

Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.

Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.

Market Dynamics: Drivers & Restraints

The growing burden of infectious diseases

If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.

As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.

In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.

Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.

High Cost of Diagnostic Tools

Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.

Segment Analysis

The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.

Blood Culture Media segment is expected to dominate the market growth

Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.

While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the sepsis diagnostic market share

North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.

Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.

Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Product

Instruments

Software

Blood Culture Media

Assays & Reagents

Others

By Technology

Flow Cytometry

Microbiology

Biomarkers

Molecular Diagnostics

Microfluidics

Others

By Pathogen

Automated Diagnostics

Conventional Diagnostics

By Diagnostic Method

Fungal Sepsis

Bacterial Sepsis

Gram-Positive Bacterial Sepsis

Gram-Negative Bacterial Sepsis

Other Pathogens

By End-User

Hospitals

Pathology & Reference Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMerieux SA, and Immunexpress Inc. among others.

Key Developments

On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.

On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.

Why Purchase the Report?

To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Diagnostic Method
  • 3.4. Snippet by Technology
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing burden of infectious diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnostic tools
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Instruments *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Software
  • 6.4. Blood Culture Media
  • 6.5. Assays & Reagents
  • 6.6. Others

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Flow Cytometry*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Microbiology
  • 7.4. Biomarkers
  • 7.5. Molecular Diagnostics
  • 7.6. Microfluidics
  • 7.7. Others

8. By Diagnostic Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 8.1.2. Market Attractiveness Index, By Diagnostic Method
  • 8.2. Automated Diagnostics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Conventional Diagnostics

9. By Pathogen

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 9.1.2. Market Attractiveness Index, By Pathogen
  • 9.2. Fungal Sepsis*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Bacterial Sepsis
    • 9.3.1. Gram-Positive Bacterial Sepsis
    • 9.3.2. Gram-Negative Bacterial Sepsis
  • 9.4. Other Pathogens

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Pathology & Reference Laboratories
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
      • 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.2.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
      • 11.2.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.4.1. U.S.
      • 11.2.4.2. Canada
      • 11.2.4.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
      • 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.3.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. UK
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
      • 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.4.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
      • 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.5.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
      • 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.6.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
      • 11.6.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Bruker Corporation
  • 13.3. Merck Millipore
  • 13.4. Siemens Healthineers
  • 13.5. Becton, Dickinson, and Company
  • 13.6. Hoffmann-LA Roche Ltd
  • 13.7. T2 Biosystems, Inc.
  • 13.8. Response Biomedical Corp.
  • 13.9. BioMerieux SA
  • 13.10. Immunexpress Inc. (LIST NOT EXHAUSTIVE)

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us